Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed) | RFA DK 27 302

Opportunity Information: Apply for RFA DK 27 302

The National Institutes of Health (NIH) is soliciting applications under the Kidney Precision Medicine Project (KPMP) for Tissue Interrogation Sites (TIS) through a cooperative agreement mechanism (U01). The purpose of these awards is to support teams that can apply tightly coordinated, multi-modal analytical pipelines to human kidney biopsy tissue, with the goal of discovering and defining previously unrecognized disease pathways and biologically meaningful patient subgroups. In practical terms, the program is aimed at generating a deeper, more precise understanding of kidney disease biology that can ultimately inform the design of precision-focused clinical trials, even though the funding opportunity itself is explicitly labeled "Clinical Trial Not Allowed."

A central expectation of this opportunity is high integration across methods and data types. Applicants are expected to interrogate kidney tissue using complementary approaches (for example, combining molecular, cellular, spatial, and computational analyses) in a way that produces coherent, interoperable outputs rather than isolated datasets. These Tissue Interrogation Sites are positioned as key discovery engines within KPMP, contributing analyses that help refine disease definitions and identify actionable mechanisms. Because the award is a cooperative agreement, awardees should anticipate substantial programmatic involvement and collaboration with NIH and the broader KPMP consortium, rather than operating as fully independent, stand-alone research projects.

KPMP also places strong emphasis on team science and open science. The NOFO states that all KPMP personnel will actively participate in scientific discovery and promote open science, which typically implies active cross-site collaboration, use of shared standards, timely sharing of data and methods, and participation in consortium-wide activities that accelerate collective progress. Applicants should be prepared for coordinated planning, harmonized workflows, and ongoing contributions to shared program goals, not just local site-specific objectives.

Eligibility is broad across U.S.-based organization types, including various levels of government (state, county, city/township), special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (both 501(c)(3) and non-501(c)(3)), for-profit organizations (including small businesses and other for-profits that are not small businesses), public housing authorities/Indian housing authorities, and Native American tribal governments and organizations (including federally recognized tribal governments and other tribal organizations). At the same time, the NOFO is explicit about restrictions on international participation: non-U.S. (foreign) organizations are not eligible to apply; non-U.S. components of U.S. organizations are not eligible; and foreign components as defined by the NIH Grants Policy Statement are not allowed. Applicants should review Section III (Eligibility Information) of the NOFO carefully to confirm that their institutional structure and proposed work do not trigger any of these prohibitions.

Key administrative details include the funding opportunity number RFA-DK-27-302 and the CFDA number 93.847. The opportunity is categorized as discretionary funding and uses the cooperative agreement funding instrument. NIH anticipates making 2 awards, with an award ceiling of $1,500,000. The original closing date for applications is July 10, 2026, and the opportunity record lists a creation date of June 3, 2026. Overall, this NOFO is geared toward a small number of highly capable, collaborative sites that can deliver sophisticated, standardized tissue interrogation outputs that feed directly into KPMPs larger precision medicine strategy for kidney disease.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2026-06-03.
• Applicants must submit their applications by 2026-07-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 27 302

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: